- Home
- SRV vs INMB Comparison
SRV vs INMB Comparison
Compare SRV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.9M | 64.7M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRV | INMB |
|---|---|---|
| Price | $44.49 | $2.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 45.7K | ★ 327.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $38.11 | $1.09 |
| 52 Week High | $51.54 | $2.60 |
Technical Indicators
Market Signals| Indicator | SRV | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 54.39 |
| Support Level | $44.01 | $2.21 |
| Resistance Level | $46.19 | $2.55 |
| Average True Range (ATR) | 1.05 | 0.15 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 25.62 | 58.27 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end investment company. Its investment objective is to obtain a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in a portfolio of midstream energy investments.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.